A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2006
10/19/2006	US20060233806 Removal promoters and inhibitor for apoptosis cells in vivo
10/19/2006	US20060233804 IGF antagonist peptides
10/19/2006	US20060233799 Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases
10/19/2006	US20060233796 Method of modulating memory effector T-cells and compositions
10/19/2006	US20060233792 novel tumor necrosis factor receptor (TRAIN-R) for treating inflammatory bowel disease and arthritic condition; antiinflammatory agents
10/19/2006	US20060233762 Method for treating or preventing systemic inflammation in formula-fed infants
10/19/2006	US20060233753 Administering an adenovirus defective in its VAI and VAII virus-associated RNAs
10/19/2006	US20060233743 Compositions and methods of therapy
10/19/2006	US20060233735 Psoriasis; applying daily to hair an aqueous mixture of clobetasol propionate, an anionic surfactant, an amphoteric surfactant, and ethanol; leaving it for 2.5 to 15 minutes, and rinsing with water.
10/19/2006	US20060233723 Mouth and/or throat wash
10/19/2006	US20060233719 Delivery of antidepressants through an inhalation route
10/19/2006	US20060233710 Prevention and treatment for GVHD
10/19/2006	DE112004001502T5 Neurobeschützende und Anti-Proliferationsverbindungen Neurobeschützende and anti-proliferative compounds
10/19/2006	DE102005017592A1 Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem Dosage forms and compounds of Pyrimidinbiosyntheseinhibitoren to generate additional effects on the immune system
10/19/2006	DE102005016981A1 Kombination zur Therapie bei benigner Prostatahyperplasie Combination for treatment of benign prostatic hyperplasia
10/19/2006	CA2604536A1 Conjugate comprising p21 protein for the treatment of cancer
10/19/2006	CA2604381A1 Use of growth hormone antagonist and somatostatin agonist
10/19/2006	CA2604187A1 Selection of highly efficient antigen presenting cells for regulating immunity and uses thereof
10/19/2006	CA2600709A1 Use of cd25 antibodies in immunotherapy
10/19/2006	CA2584075A1 Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
10/18/2006	EP1712634A1 Selection of highly efficient antigen presenting cells for regulating immunity and uses thereof
10/18/2006	EP1712619A1 Preventive/remedy for cancer
10/18/2006	EP1712566A1 Inflammatory cytokine inhibitor
10/18/2006	EP1712242A1 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
10/18/2006	EP1712234A1 Use of 4-Pyridylmethylphthalazines for Cancer Treatment
10/18/2006	EP1712232A1 Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
10/18/2006	EP1712225A1 Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists
10/18/2006	EP1711618A1 Methods for detecting markers associated with endometrial disease or phase
10/18/2006	EP1711518A2 Chimpanzee adenovirus vaccine carriers
10/18/2006	EP1711457A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
10/18/2006	EP1711454A1 Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
10/18/2006	EP1711210A2 Combined use of prame inhibitors and hdac inhibitors
10/18/2006	EP1711209A1 Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
10/18/2006	EP1711197A1 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
10/18/2006	EP1711178A1 Compositions substantially free of galactomannan containing piperacillin and tazobactam
10/18/2006	EP1711176A1 Immunomodulatory alkaloids
10/18/2006	EP1711174A1 Adjuvant compositions
10/18/2006	EP1711172A2 Compositions and methods for combined therapy of disease
10/18/2006	EP1711161A2 Methods of preventing and treating sars using low ph respiratory tract compositions
10/18/2006	EP1711157A1 Composition for treating a dermatological inflammatory response and method of preparation thereof
10/18/2006	EP1711054A1 Method and compositions for treatment of painful disorders
10/18/2006	EP1345932B1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
10/18/2006	EP1339714B1 Novel sulfonamide-substituted pyrazolopyridine derivatives
10/18/2006	EP1280821B1 Dna molecules encoding ligand gated ion channels from dermacentor variabilis
10/18/2006	EP1212070B1 Plant extract mixtures (cissus, vernonia, brillantaisia) and their uses
10/18/2006	EP1208196B1 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
10/18/2006	EP1180039B1 Composition for the treatment of a neurological disorder
10/18/2006	EP1165778B1 Uses of casb618 polynucleotides and polypeptides
10/18/2006	EP1141286B1 Cytokine receptor chain
10/18/2006	EP1084710B1 Adenosine a1 antagonists for male sterility
10/18/2006	EP1042468B1 Low-voltage activated calcium channel compositions and methods
10/18/2006	EP1004667B1 Cell cycle-regulating proteins
10/18/2006	CN1849153A Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
10/18/2006	CN1849142A 2'-branched nucleosides and flaviviridae mutation
10/18/2006	CN1849140A Bitterness-masking particulate jelly beverage
10/18/2006	CN1849126A 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
10/18/2006	CN1849122A Method of treating cancer using fpt inhibitors and at least two antineoplastic agents
10/18/2006	CN1849119A Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
10/18/2006	CN1849112A Therapeutic liposomes
10/18/2006	CN1847253A Process for preparing amine platinum complexes
10/18/2006	CN1846718A Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
10/18/2006	CN1846691A Long circulation liposome with modified integrin and carried anticancer medicine for injection
10/18/2006	CN1846689A Slow-released anticancer prepn containing taxane and its synergist
10/18/2006	CN1846688A Slow-released anticancer prepn containing taxane and its synergist
10/18/2006	CN1846687A Slow-released prepn containing taxane and its synergist
10/18/2006	CN1846686A Slow-released injection containing taxol and its synergist
10/18/2006	CN1846685A Slow-released injection containing bendamustine and its synergist
10/18/2006	CN1846684A Slow-released injection containing methotrexate synergist
10/18/2006	CN1846683A Slow-released injection containing methotrexate synergist
10/18/2006	CN1846682A Slow-released anticancer prepn containing methotrexate
10/18/2006	CN1846681A Slow-released injection containing methotrexate and its synergist
10/18/2006	CN1846680A Slow-released methotrexate injection
10/18/2006	CN1846679A Slow-released injection containing methotrexate and its synergist
10/18/2006	CN1846678A Slow-released anticancer injection
10/18/2006	CN1846677A Slow-released injection containing fluoroplex synergist
10/18/2006	CN1846676A Slow-released injection containing fluoroplex synergist and its prepn process
10/18/2006	CN1846675A Slow-released anticancer medicine prepn containing 5-Fu synergist
10/18/2006	CN1846674A Slow-released anticancer medicine injection
10/18/2006	CN1846673A Slow-released anticancer medicine prepn containing pyrimidine medicine
10/18/2006	CN1846672A Anticancer medicine composition containing antimetabolite
10/18/2006	CN1846670A Anticancer implant
10/18/2006	CN1846668A Controlled releasing penetrant pump prepn for insoluble medicine composition
10/18/2006	CN1280307C Cytotoxin T lymphocyte
10/18/2006	CN1280266C Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals
10/18/2006	CN1280259C Aryl aniline beta-2 adrenergic receptor agonists
10/18/2006	CN1279980C Anti solid tumor medicine composition
10/18/2006	CN1279979C Nucleic vaccine for tubercle bacillus
10/18/2006	CN1279923C Human body lubricant of containing fucose and hyaluronic acid, and its prepn. method
10/18/2006	CN1279891C Use of water solution containing positive ion cellulose polymer in preparation of drug for treating dry eye
10/18/2006	CN1279843C Dietary compositions and methods
10/17/2006	US7122677 NK1 antagonists
10/17/2006	US7122654 Hybrid; adjust vascular system permeability
10/17/2006	US7122652 Isolated polynucleotide encoding a variant human pregnane X receptor (hPXR) polypeptide or fragment; detection and genotyping of hPXR alleles in humans, homozygous as well as heterozygous, alleles of the hPXR gene
10/17/2006	US7122635 Method and composition for angiogenesis inhibition
10/17/2006	US7122629 For forensic analyses, chromosome tissue/cell/organelle-specific markers, production of expression vectors, screening and diagnosis assays
10/17/2006	US7122579 Eye treatments using synthetic thyroid hormone compositions
10/17/2006	US7122578 Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
10/17/2006	US7122574 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents
10/17/2006	US7122558 Anticholinergic agents; chronic obstructive pulmonary diseases; incontinence; gastrointestinal disorders; antiulcer agents; cardiovascular disorders
10/17/2006	US7122544 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto

1 ... 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 ... 1151